ALGS Aligos Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALGS

Price (delayed)

$5.29

Market cap

$32.74M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.79

Enterprise value

$6.93M

?
Relative Growth: Rel. Growth: 40
Relative Strength: Rel. Strength: 9
Relative Valuation: Rel. Valuation: 9
Relative Profitability: Rel. Profitability: 21

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver ...

Highlights
ALGS's revenue has soared by 115% since the previous quarter and by 44% year-on-year
ALGS's gross profit has surged by 115% since the previous quarter and by 44% year-on-year
Aligos Therapeutics's equity has shrunk by 73% YoY and by 41% QoQ
Aligos Therapeutics's net income has shrunk by 70% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.aligos.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of ALGS

ALGS stock price

How has the Aligos Therapeutics stock price performed over time
Intraday
2.92%
1 week
-8.64%
1 month
-17.86%
1 year
-15.9%
YTD
-43.24%
QTD
-28.8%

Financial performance

How have Aligos Therapeutics's revenue and profit performed over time
Revenue
$4.71M
Gross profit
$4.71M
Operating income
-$95.67M
Net income
-$90.32M
Gross margin
100%
Net margin
-1,919.7%
ALGS's revenue has soared by 115% since the previous quarter and by 44% year-on-year
ALGS's gross profit has surged by 115% since the previous quarter and by 44% year-on-year
The company's net margin has shrunk by 73% QoQ and by 18% YoY
Aligos Therapeutics's net income has shrunk by 70% YoY

Price vs fundamentals

How does ALGS's price correlate with its fundamentals

Growth

What is Aligos Therapeutics's growth rate over time

Valuation

What is Aligos Therapeutics stock price valuation
P/E
N/A
P/B
1.03
P/S
11.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.47
Aligos Therapeutics's EPS has increased by 14% YoY
Aligos Therapeutics's equity has shrunk by 73% YoY and by 41% QoQ
The stock's price to book (P/B) is 11% more than its last 4 quarters average of 0.9 but 9% less than its 5-year quarterly average of 1.1
ALGS's revenue has soared by 115% since the previous quarter and by 44% year-on-year
The stock's price to sales (P/S) is 73% less than its 5-year quarterly average of 42.8 and 62% less than its last 4 quarters average of 30.1

Efficiency

How efficient is Aligos Therapeutics business performance
ALGS's return on assets has dropped by 78% year-on-year
Aligos Therapeutics's ROS has plunged by 56% from the previous quarter and by 15% YoY
The return on equity has declined by 34% year-on-year
The company's return on invested capital fell by 30% YoY

Dividends

What is ALGS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALGS.

Financial health

How did Aligos Therapeutics financials performed over time
The total assets is 97% more than the total liabilities
ALGS's quick ratio has dropped by 68% year-on-year and by 36% since the previous quarter
ALGS's current ratio has dropped by 66% year-on-year and by 34% since the previous quarter
The company's debt is 86% lower than its equity
ALGS's debt to equity has soared by 100% YoY and by 40% QoQ
Aligos Therapeutics's equity has shrunk by 73% YoY and by 41% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.